Racing CARs to veterinary immuno-oncology

Area of Science:

• Veterinary Oncology
• Immunotherapy
• Molecular Engineering

Background:

• Chimeric antigen receptor (CAR) T cell therapy has shown significant success in human oncology over the last 20 years.
• CARs are engineered proteins that redirect T cells to target and eliminate cancer cells, particularly hematological malignancies.
• While FDA-approved for human use, CAR T therapy translation to veterinary medicine is still in early developmental stages.

Purpose of the Study:

• To review the current status and challenges of CAR T cell therapy in veterinary oncology.
• To discuss key considerations for adapting CAR T cell therapy for animal patients.
• To explore the future potential of CAR T cell therapy in veterinary cancer treatment.

Main Methods:

• Review of existing literature on CAR T cell therapy in human and veterinary medicine.
• Analysis of CAR design principles and cell carrier selection relevant to veterinary applications.
• Discussion of regulatory and technical hurdles for veterinary CAR T therapy.

Main Results:

• CAR T cell therapy holds significant potential for treating various cancers in animals.
• Key challenges include CAR design optimization, appropriate cell carrier selection, and addressing potential toxicities in veterinary patients.
• Successful translation requires overcoming specific biological and logistical obstacles in animal models.

Conclusions:

• CAR T cell therapy represents a promising frontier in veterinary oncology, offering a novel approach to cancer treatment.
• Further research and development are crucial to overcome existing challenges and realize the full therapeutic potential in animals.
• The review highlights the need for tailored strategies to effectively implement CAR T cell therapy in veterinary cancer care.